Pharmacological Study That Measures Omeprazole Effect on Aspirins Absorption in Healthy Volunteers
|ClinicalTrials.gov Identifier: NCT01061034|
Recruitment Status : Completed
First Posted : February 2, 2010
Results First Posted : February 2, 2010
Last Update Posted : February 2, 2010
Aspirin is a weak acid that crosses the gastric and intestinal mucosa by passive diffusion while in its lipophilic nature.Omeprazole, a proton pump inhibitor, inhibits gastric acid secretion.
We assumed that omeprazole inhibits aspirin absorption, thus reducing its action on platelets.
healthy volunteers, with no known peptic disease or bleeding disorders will be enrolled.
All volunteers will receive 7 days of Aspirin (100mg) alone, followed by 14 days of Aspirin and Omeprazole 20mg twice daily for 3 days and then 20mg once daily.
Blood levels of Aspirin will be determined by High performance liquid chromatography (HPLC), 0, 1, 2, 4, 6, 10, 24 hours after the administration of Aspirin alone on day 7 and Aspirin plus Omeprazole on day 21.
Platelet function tests will be determined by platelet-rich plasma aggregometry in response to Arachidonic acid (500mg/ml), Ristocetin (1.5mg/ml) and Adenosine 5'-diphosphate (20mM) on day 0 as baseline and on day 7 and 21 of the study.
|Condition or disease||Intervention/treatment||Phase|
|Aspirin Blood Level Proton Pump Inhiditor Treatment||Drug: aspirin and omeprazole||Not Applicable|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||9 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||The Effect of Proton Pump Inhibitor (Omeprazole) on Acetosalisylic Acid Absorption.|
|Study Start Date :||March 2007|
|Actual Primary Completion Date :||June 2007|
|Actual Study Completion Date :||June 2007|
- Drug: aspirin and omeprazole
aspirin 100 mg, once daily aspirin 100 mg and omeprazole 20 mg both once daily.
- Aspirin Level in Blood (Area Under the Curve) [ Time Frame: on day 7,on day 21 ]
Aspirins pharmacokinetics: aspirin blood level determined by use of high performance liquid chromatography (HPLC) at baseline, 1, 2,4,6,10 and 24 hours after administration of aspirin on day 7 and on day 21.
The area unther the time vs. concentration curve of the reccurent measurments(AUC) reflects bioavailability of aspirin.
- Platelet Function Tests [ Time Frame: on day 0 as a baseline and on day 7 and 21 of the study. ]
Platelet function tests were determined by optical whole blood aggregometry in response to arachidonic acid and adenosine diphosphate.
the results reflects the percent of active platelets.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01061034
|Assaf Harofeh Medical Center|
|Study Director:||ahuva golik, prop.||asaf-harofemedical center|